Ras GTPases convey signals from different types of membranes. At these locations, different Ras isoforms, interactors and regulators generate different biochemical signals and biological outputs. The study of Ras localisation-specific signal transduction networks has been hampered by our inability to specifically activate each of these Ras pools. Here, we describe a new set of site-specific tethered exchange factors, engineered by fusing the RasGRF1 CDC25 domain to sub-localisation-defining tethers, whereby Ras pools at specific locations can be precisely activated. The CDC25 domain has a high specificity for activating HRas but no NRas and KRas. This unexpected finding means that the CDC25 tether constructs mainly activate endogenous H-Ras. Hence, the use of these constructs enabled us to identify distinct pathways regulated by HRas in endomembranes and plasma membrane microdomains. Importantly, these new constructs unveil different patterns of HRas activity specified by their subcellular localisation. Overall, the targeted GEFs described herein constitute ideal tools for dissecting spatially-defined HRas biochemical and biological functions
INTRODUCTION
The proteins of the Ras family of small GTPases, including HRas, KRas4A, KRas4B and NRas, function as molecular switches 1 . Mutations in these proteins occur in over 30% of human tumours and Ras oncogenic mutants are some of the main drivers of cancer 2, 3 . Under physiological conditions, Ras cycles between an active state, bound to GTP, and an inactive state, bound to GDP. The Ras activation/deactivation cycle is tightly regulated by two classes of proteins, Guanine Exchange Factors (GEFs), which facilitate Ras activation, and GTPase
Activating Proteins (GAPs), which increase Ras GTPase activity, leading to Ras inactivation 2 . Ras proteins regulate a complex signalling network mediated by several effectors including the Raf family kinases, phosphoinositide-3 Kinase (PI3K) and Ral exchange factors. Ras signalling networks ultimately regulate multiple biological responses, including key events such as proliferation, differentiation, migration or survival 2 . Thus, a refined control of the activity of Ras proteins is crucial for eliciting the correct cell fate decision. Control mechanisms operate at different tiers in order to orchestrate specific Rasdependent responses, through differential interaction with different effector and regulatory proteins 4 . Another important mechanism for regulating Ras signalling is the localisationspecific control of Ras activation at different membrane domains within the cell, due to the spatially-defined participation of certain exchange factors 5, 6 .
Previous studies have unveiled the importance of the site from which Ras signals originate.
Initially, it was thought that Ras was functional only at the peripheral plasma membrane, where GEFs would be active 7 , but in recent years it has been demonstrated that Ras can also signal from internal localizations such as endoplasmic reticulum (ER) 5 , Golgi complex (GC)
patterns. HRas and NRas signal from the ER and the GA while KRas signalling is mainly evoked from plasma membrane and mitochondria 12 . Although some Ras interactors are present in all known Ras localisations, a substantial body of data indicates that Ras proteins interact with diverse sets of proteins at distinct sub-localisations, thereby eliciting specific signals from different platforms 12 . Unfortunately, a clear notion of the contribution of the different spatially-defined Ras pools to specific functions is limited by the technical inability to activate the endogenous Ras proteins at, and only at, a specific location. Thus, most of the work done to decipher Ras spatial signalling has been performed by overexpressing tagged constitutively-activated Ras proteins sent to the desired sub-localisations using specific localisation tethers. Such an approach has caveats, since overexpression of these constructs may lead to signal distortions resulting from alterations in Ras regulatory mechanisms such as negative feedback loops. 13 In this respect, we have previously reported a comprehensive analysis of HRas site specific signalling by using the constitutively activated mutant HRasG12V, which led us to identify several HRas-dependent functions that are mediated by different spatially-defined HRas pools 8, 14, 15 . However, such an approach has pitfalls, since in that scenario negative and positive feedback loops modulating Ras signalling may be lost. In addition, HRas-V12 may exhibit different affinity and kinetics for Ras interacting protein compared to wild type HRas 16 . Thus, signals triggered by mutant Ras at specific locations may differ from those evoked by wt HRas due to their different affinities for GEFs 5, 6, 17 and GAPs [18] [19] [20] , scaffold proteins 21 and effectors 5, 6, 22, 23 . Therefore, there is an urgent need to develop new methods and strategies in order to characterise local signalling networks activated by Ras under physiological settings.
Here, we present a new set of molecular tools that enable the study of the signalling pathways triggered by endogenous Ras at specific sub-localisations. We demonstrate that these constructs preferentially activate endogenous HRas. Importantly, the signalling networks activated by endogenous HRas reveal similarities but also remarkable differences with those networks evoked by ectopic, site-specific-HRasV12 constructs.
RESULTS
Engineering site-specific Ras activator constructs.
In order to study the signals generated by endogenous Ras populations present at their physiological localisations, we engineered a novel set of molecular utensils based on the RasGRF1 CDC25 catalytic domain. It is known that overexpression of an isolated CDC25 domain targeted to the plasma membrane (PM) is sufficient for activating endogenous Ras 24 .
Indeed, we ascertained that the expression of CDC25 caused an increase of RAS-GTP levels similar to those elicited by the whole RasGRF1 protein ( Figure 1A ). We reasoned that the CDC25 domain specifically targeted to different types of membranes, would be capable of specifically activating the endogenous Ras pools therein, while unaltering physiological regulatory mechanisms acting on RAS signals, such as negative and positive feedbacks or GAPs intervention. To this end, the CDC25 domain was fused to the site-specific tethers previously used to successfully target wt HRas and HRas-V12 to different cellular compartments 14 . These cues comprised: the avian infectious bronchitis virus M protein (referred as M1-CDC25 hereafter) to target CDC25 to the endoplasmic reticulum (ER) 25 . For stable expression at the Golgi complex (GC) we used KDEL receptor D193N mutant 6, 26 (KDEL-CDC25). At the PM we analysed two different domains: disordered membrane (DM), using the transmembrane region of the CD8α receptoranchored the CDC25 domain to lipid rafts (LR) using LCK myristoylation signal 28, 29 (LCK-CDC25). A FLAG tag was included to enable the detection of the targeted proteins.
To test that the constructs were correctly expressed and localised to the desired locations they were transiently transfected in HEK293T cells and their expression was monitored by western blot (Fig. 1B upper panel) . In parallel, we ascertained their localisation by immunofluorescence using anti-FLAG staining in transfected Cos-1 cells by testing their colocalisation with targeted HA-HRas-wt or specific localisation markers. We observed that the targeted CDC25 proteins specifically localised at the desired localisations with similar expression patterns as those previously described for the HRAS V12 constructs 5 ( Fig. 1C ).
In addition, we generated HeLa cell lines stably expressing the different site-specific GEFs.
In these, the expression levels were lower than those obtained by transient expression. In fact, expression was only detectable by previously performing an anti-FLAG immunoprecipitation. (Fig. 1B lower panel) .
Altogether, these results indicated that the CDC25 tagged constructs were properly expressed and specifically localized to those compartments where they were aimed at.
Sublocalisation-targeted GEFs specifically activate HRas at different compartments.
Previous studies have shown that RasGRF1 specifically activates HRas, but not NRas and KRas 30, 31 . However, it is unclear why Ras-GRF1 shows such preferences. Structural studies comparing the CDC25 domains of Ras-GRF and SOS1, suggest that such affinity is not dictated by this domain, requiring the participation of other regulatory motifs present in the GEF 32 . For this reason, we expected our constructs to activate the three Ras isoforms. To confirm this, we analysed the ability of untethered, "global" FLAG-CDC25 to activate the three RAS isoforms, by performing Ras-GTP pull down assays in HEK293T cells transiently expressing the GEF plus wild-type versions of H, K and NRas ( Figure 2A 33 . Importantly, this data indicated that the CDC25 domain can contribute to isoform specificity in vivo. These data demonstrated that the CDC25-based constructs are particularly suited for the study of HRas, and therefore we focused on this isoform for the rest of the study.
Next, we investigated the ability of the different site-specific CDC25 constructs to activate the corresponding pools of endogenous HRas. To this end, we utilized the stable HeLa cell lines in which we analysed HRAS activation by Ras-GTP pull-down using GST-Raf-RBD.
We found that, compared to parental cells, endogenous HRas activation was augmented in all cases, though to different extents. In this cellular context, the ER and DM exhibited the highest levels of Ras activation ( Figure 2B ). These results could reflect that, in HeLa cells,
HRas is enriched at those sub-localisations where activation is more prominent.
Unfortunately, as of today, there is no reliable methodology to quantitate and compare the levels of endogenous Ras proteins existing at different sub-localisations.
It was important to verify that the thethered-CDC25 constructs activated HRas only at the desired localisation and not unspecifically at other localisations. To test this, the locationspecific HRAS wild-type versions: M1-HA-HRas (ER-R), LCK-HA-HRas (LR-R), CD8-HA-HRas (DM-R), or KDEL-HA-HRas (GC-R), were co-transfected with the targeted CDC25 proteins. Analysis of their activation in serum deprived HEK293 cells, confirmed that they were highly GTP-loaded when co-expressed with the CDC25 construct bearing the same tether.
Interestingly, we found that globally expressed CDC25 (TOT-CDC25) activated endogenous
Ras to a lesser extent than the site-specific CDC25 constructs (Fig. 2B ), except when targeted to LRs (Fig. 2C ), suggesting that untargeted CDC25 mainly activates HRas at this sublocalisation.
Noticeably, some unspecific activation was apparent, especially in the case of PM microdomains ( Fig. 2C ). This could be due to the cross-activation of HRas pools located at the boundaries of DM and LR microdomains. In addition, vesicle trafficking between endomembranes and the peripheral PM may also contribute to some unspecific activation of
HRas by reshuffling the localisation of the CDC25 constructs.
In summary, these experiments strongly indicated that the location-specific CDC25
constructs mainly activate the HRas pool located at the specific sublocalisation where these proteins are expressed.
Ras effectors are differentially regulated depending on the subcellular localization where endogenous Ras is activated.
Next, we tested whether the activation of endogenous HRas at different subcellular compartments could differentially activate known Ras effector pathways. Our previous studies of KRas-dependent regulation of RASSF1A/MST2 demonstrated the importance of the differences on the activation kinetics of oncogenic vs wild-type Ras in the regulation of cell death and proliferation 16, 34 . This study also demonstrated that the dynamics and magnitude of Ras signalling network could be cell type specific. Therefore, we compared effector usage in response to endogenous, site-specific HRas activation, as evoked by the tethered CDC25 constructs, to that elicited by the presence of ectopic HRasV12 at the same sites. We performed these experiments in NIH-3T3 cells, previously used to characterise effector pathway activation by tethered HRasV12 constructs 14 . We found that both sets of constructs elicited a similar pattern of ERK1/2 activation (Fig. 3A) . Interestingly, in the case of ER-emanating signals, endogenous HRAS was more efficient than its oncogenic version for triggering ERK activation. Overall, notwithstanding expected differences in intensities, endogenous RAS activation, as evoked by site-specific GEFs, and site-restricted HRasV12
oncoproteins elicit similar patterns of ERK activation.
We extended our analyses to other well-characterised Ras effectors, by monitoring the changes on AKT phosphorylation, one of the key components of the PI3K cascade. The phosphorylation status of AKT exhibited remarkable differences when elicited by endogenous HRas activated by the targeted GEFs at different locations. Interestingly, the two phosphorylatable residues needed for full activation of the kinase [35] [36] [37] , threonine 308 (T308) and serine 473 (S473), exhibited distinct phosphorylation patterns depending on the sublocalisation where HRas was activated (Fig 3B) . While PDK1-dependent T308 phosphorylation 38 was mainly evoked from LR, where PDK1 is located 39 , S473
phosphorylation mainly resulted as a consequence of HRas signals coming from disordered membrane and endomembranes but not from LR ( Fig. 3B upper panel) . Since AKT-S473 is phosphorylated by mTORC2 36 , our results are in line with previous reports indicating that AKT-T308 and S473 residues may be phosphorylated in different cell compartments due to differential localisation of PDK1 and mTORC2 40, 41 . In the case of mTORC2 which localises to endomembranes, and possibly at some specific PM domains, it suggests that this kinase could be activated by HRas-induced mechanisms at these locations. Thus, these results shed light on the relevance of mTORC2 localization at the PM, hitherto not well characterised. It has been proposed that mTORC2 is recruited to LR by AKT and that this complex may translocate to disordered membrane upon activation to allow its dephosphorylation 40, 41 . Our results would confirm that mTORC2 is differentially activated at PM microdomains, but contrary to previous reports, they strongly indicate that the activation of mTORC2 induced by HRas 42 occurs at the DM.
The suitability of the site-specific GEFs for deciphering localized HRas signalling, was further confirmed when we studied the activation of the stress activated kinase JNK1. We observed that JNK was differentially regulated, to some extent, from all locations. Although the site-related difference on JNK activation are small, we consistently observed that activation from GC significantly evoked higher levels of phosphorylated JNK (Fig. 3B middle) while JNK activity by HRas activation at ER and DM was less potent. In addition,
we analysed STAT3 phosphorylation (Y705) after local HRas activation. This phosphorylation has been reported to be responsible for its dimerization, translocation to the nucleus and DNA binding, which is essential for STAT3-dependent regulation of cell cycle and survival genes [43] [44] [45] . We found that site-specific GEFs induced STAT3 phosphorylation, preferentially from the GC (Fig. 3B lower panel) .
The above results confirmed that endogenous HRas activates different signalling pathways at distinct cellular localisation. Importantly, these results showed some differences on the pattern of activation of HRas signalling pathways compared to what we observed in our previous studies using constructs expressing site-specific HRasV12 14 . The fact that we did not find the same pattern of effector activation suggest that wild-type and oncogenic HRas are not equivalent in their regulation of effector networks, something that could be related to cellular transformation and other cancer-related processes. Altogether, our data demonstrate that our site-specific GEFs are useful tools for the study of HRas signalling variability as orchestrated by space.
Regulation of proliferation and survival by Ras activity induced by site-specific GEFs.
We next used the CDC25 targeted constructs to investigate the contribution of the different subcellular pools of endogenous HRas to several biological outcomes.
Our previous studies using NIH3T3 stable cell lines expressing targeted HRasV12 proteins, demonstrated that proliferation was differentially regulated depending on localisation 14 . For this reason, we analysed if activation of endogenous HRas by the site-specific GEFs followed the same pattern. We found that Ras signalling from PM microdomains (LR and DM) had the highest impact on proliferation (Fig. 4A ). This result was identical to that we had previously observed when using targeted-HRasV12 14 . It confirmed that constant HRas activation from the PM evokes a proliferative advantage, regardless whether the HRas activation is caused by mutation or chronic GEF stimulation.
Next, we examined cell survival using two different assays. First, we measured the bulk survival rates of confluent cells expressing the different targeted CDC25 constructs under conditions of serum depravation (Fig. 4B) . In this case, we did not observe significant differences. However, when we measured clonal survival by colony formation assays, where cells are evaluated for their capacity to survive and form colonies originating from single cells. Our data showed that CDC25 chronic activation of HRas provided pro-survival signals from LR, DM and GA but not from the ER (Fig. 4C) . Significantly, this result is very different from our previous observations using the oncogenic HRas constructs, where we saw a clear pro-survival advantage emanating from the ER and no regulation from the GA 14 . This difference suggested the existence at the ER of a down-regulatory mechanism of HRas signals that modulates this biological function. Interestingly, the results might indicate that oncogenic HRasV12 is insensitive to such feedback regulation triggering pro-survival signals from the ER that may contribute to HRasV12-dependent transformation. Distinguishing between these possibilities will require the identification of the feedback loop in future studies.
Targeted-CDC25 overexpression does not confer transforming properties.
Constitutively active HRas-V12 is a driver of cell transformation 1 , primarily due to aberrant regulation of the activation status of its effector pathways 46 . It has also been reported that expression of full length RasGRF1 and the isolated CDC25 catalytic domain could transform NIH3T3 cells due to hyperactivation of HRas signalling 24, 47 . For this reason, we next examined whether CDC25-induced transformation was differentially regulated by specific HRas pools. To this end, we performed focus formation assays in NIH3T3 fibroblasts using the bona fide oncogene HRasV12 as positive control 1 . Surprisingly, contrary to previous studies demonstrating that the expression of an isolated CDC25 domain induces transformation in NIH3T3 cells 7 , our results clearly showed that overexpression of the CDC25 GEF motif did not result in cellular transformation (Fig. 5 ). The discrepancy between both studies is likely due to differences on the sequences spamming by the CDC25 domain on both cases. Similarly, no transformation of NIH3T3 was observed when we expressed the site-specific constructs.
Hence, our findings showed that the targeted CDC25-GEF domains can induce activation of endogenous HRas but, unlike hyperactive HRasV12 this does not result in cellular transformation.
Discussion.
Our understanding of the functional differences among Ras isoforms has increased since the seminal studies by Mark Phillips and John Hancock demonstrated that Ras are active in endomembranes and in different PM microdomains 48, 49 , where they have different sets of interactors. Unfortunately, despite the growing importance of space as a regulator of Ras signalling, we still lack the technology to specifically and physiologically activate compartmentalised pools of Ras. For this reason we must rely on the use of different molecular tools to decipher Ras spatial regulation. Therefore, the CDC25-based site-specific constructs described herein are valuable tools for this purpose. These constructs are an important addition to the series of molecular tools that we and others have developed in the past, to understand the role of the different cellular pools of Ras in the diverse plethora of biological outcomes regulated by these proteins 5, 11, 13, 14 . Unexpectedly, we found that the CDC25 domain cloned here shows strong specificity for HRas and only when the constructs were expressed and high levels in the cells we could see a modest activation of the endogenous NRas and KRas. It is also important to note that the CDC25 construct generated seems to have different properties than the construct previously described by Der's group 7 .
This is clearly illustrated by one of the most surprising observation presented here, the lack of transforming properties of the CDC25 constructs that we generated does not induce cell transformation in clear contrast with previous reports. This is likely explained because the 47 .
Using these set of constructs we demonstrate that expression of site-specific CDC25 constructs trigger differential HRas-dependent functions summarised in Figure 6 .
Remarkably, these findings indicate that site-specific CDC25 constructs are appropriate tools for the study of spatially-defined HRas signalling, by generating a response closer to Finally, the current study demonstrates that the combination of these tools in comparative studies can be used to gain insights into the regulatory mechanisms regulating spatiallydefined Ras signals, and will help to decipher the spatial cues regulating oncogenic RAS transforming properties. These studies will help in completing our understanding of Rasdependent signalling networks that have not been fully characterised despite intensive work in the last three decades.
METHODS

Constructs
pGEX-Raf-RBD, HA-RasGRF1, pCEFL-FLAG-RasV12 and the RasV12 plasmids targeted to be expressed at different compartments were previously used and described 5, 14, 31 . CDC25
domain from the RasGRF1 plasmid described before 47 
Cell lysis and immunoblotting
Total cellular extracts were obtained after cell lysis with HEPES pH 7. 
Ras activity assays
Ras activity assays were performed by Raf-RBD pull-down as previously described 14 .
Briefly, cell were lysed usig magnesium rich lysis bugger (25 mM HEPES, pH 7.5, 10 mM MgCl2, 150 mM NaCl, 0.5 mM EGTA, 20 mM _-glycerophosphate, 0.5% Nonidet-P40, 10%
glycerol, 2 mM sodium orthovanadate, 1, 25 _g/ml leupeptin, and 25 _g/ml aprotinin). Cell lyses were incubated rotating for 1 hour at 4ºC with glutathione agarose beads conjugated with GST-RBD, which contains Raf's Ras binding domain. Ras-GTP bound to the GST-RBD beads was pulled-down by short centrifugations. The beads were washed three times using lysis buffer without glycerol.
Laemmli buffer was added to the dry beads and the proteins were denaturalised by boiling the samples which were next analysed by western blot. RasGTP fraction was detected with panRas antibody for the endogenous Ras or HA antibody for the transfected Ras isoforms. RasGTP levels were normalised against determined total levels of Ras in the corresponding total lysates.
Proliferation assays
Proliferation analysis was performed as previously described 14 . Briefly, NIH3T3 cells were plated at a density of 50,000 cells per well in a six-well plate in duplicates and grown in 5% FBS containing media. Every 24 hours, cells were detached and resuspended using 0.5 ml of trypsin and counted using the Countess Automated Cell Counter (Life Technologies) following manufacturer's instructions.
Survival curves
To estimate survival rates NIH3T3 cells were plated at high density in a six-well plate in duplicates and grown in 1% FBS containing media. Cells were counted every 24 hours for 3 days by standard cell counting techniques as indicated above.
G418-resistant colonies formation
Colony formation assays were performed as described previously in Matallanas et al.
14 NIH3T3 cells were plated at low confluence and transfected with 0.5 µg of the indicated plasmids. Cells were grown in DMEM supplemented with 10% calf serum in the presence of G418 (750 μg/ml) for 10-15 days to allow the formation of discrete colonies. For scoring, cells were fixed, stained with GIEMSA, and colonies with a diameter bigger than 1 mm were counted.
Transformation assays
Focus formation assay was performed as established by Aaronson et al 50 . Briefly, 30% confluent NIH3T3 were plated and transfected using Lipofectaine with the low amounts of the indicated plasmids and grown for 3 weeks in DMEM supplemented with 10% calf serum.
The media was changed every 3days and transformation of cells and the formation of foci was monitored using microscopy and visual inspection. When the focus were macroscopically detected by eye the cells were fixed and stained, and foci scored. for DM and KDEL for GC. Cells were serum deprived for 16 hours and the lysates were analysed by western blot by using specific antibodies. The blots were quantified using ImageJ and the graph shows ERK phosphorylation normalized with respect to total ERK and relative to the negative control (empty vector) in this experiment; n=3. B. Ras activation from different localisation results on distinct level of Ras targets phosphorylation. NIH3T3 cells were transfected with 0.5μg of empty vector, FLAG-CDC25 (TOT), M1-FLAG-CDC25 (ER), LCK-FLAG-CDC25 (LR), CD8-FLAG-CDC25 (DM) and KDEL-FLAG-CDC25 (GC). 24 hours post-transfection, the cells were starved for 7 hours and then lysed. Phosphorylation of the indicated proteins was determined by blotting with the indicated phospho-specific antibodies Corresponding total protein antibodies (anti-AKT, anti-JNK1 and anti-STAT3) were used for the normalization of the data. The blots where quantify using ImageJ and the numbers show fold of phosphorylation normalised with the control (-); n=3. expression of targeted CDC25 in the endoplasmic reticulum. NIH3T3 were transfected with FLAG-CDC25, M1-FLAG-CDC25, LCK-FLAG-CDC25, CD8-FLAG-CDC25 or KDEL-FLAG-CDC25 (0.5 μg/plate). Transfected cells were selected in the presence of G418 (750 μg/ml). After 12-14 days in culture, colonies were Giemsa stained, and colonies with a diameter bigger than 0.5 mm were scored. Data shows the survival as the average of number of colonies ± SD of two independent experiments. 
